文献速递肝胆胰外科围术期管理与 ERAS

锝99m-半乳糖基人血清白蛋白SPECT/CT融合成像评估残肝功能的前瞻性试验

Liver Function Assessment Using Technetium 99m-Galactosyl Single-Photon Emission Computed Tomography/CT Fusion Imaging: A Prospective Trial.
PubMed 文献 · J Am Coll Surg · 2017-09-11

这项前瞻性试验纳入185例2014至2015年间接受肝脏手术的连续患者,用锝99m-半乳糖基人血清白蛋白SPECT/CT融合成像测量残肝体积率和功能率,以残肝吲哚菁绿清除率(KGSA×功能率)预测术后残肝功能。以残肝KGSA≥0.05为安全标准,评估其准确性与可靠性,并评估90天主要并发症和死亡率。结果显示90天死亡率为0.5%,总体并发症率为9%。

要点

  • 残肝KGSA值≥0.05被用作肝切除安全性的判断标准。
  • 锝99m-半乳糖基人血清白蛋白SPECT/CT融合成像可测量残肝体积率和功能率。
  • 残肝KGSA可提供预测残肝功能的信息,辅助制定治疗方案。

核心结论

  • 残肝KGSA能提供预测残肝功能的信息,对肝病患者治疗计划的制定有重要价值。

研究设计与样本

  • 前瞻性试验纳入185例2014至2015年间接受肝脏手术的连续患者,用锝99m-半乳糖基人血清白蛋白SPECT/CT融合成像测量残肝体积率和功能率。

主要发现

  • 中位住院时间为9天,中位ICU停留时间为1天,院内死亡1例,90天死亡率为0.5%。
  • 按Clavien-Dindo分类评估的总体并发症率为9%。
  • 按国际肝脏外科学组定义,肝切除术后肝衰竭14例(8%),其中多数为B级(50%)。
  • 符合「50-50」标准的患者2例(1%),符合PeakBili>7标准的患者0例(0%)。

关键数值与推荐

  • 残肝KGSA值≥0.05时认为肝切除安全,主要终点为确定该标准的准确性和可靠性。
  • 残肝吲哚菁绿清除率用KGSA×功能率计算,用于预测未来残肝功能。

临床怎么用

  • 术前可用锝99m-半乳糖基人血清白蛋白SPECT/CT融合成像测量残肝体积率和功能率,计算残肝KGSA。
  • 残肝KGSA≥0.05可作为判断肝切除安全性的参考标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prediction of postoperative liver function remains a largely subjective practice based on CT volumetric analysis. However, future liver volume after a hepatectomy is not the only factor that contributes to postoperative liver function and outcomes. STUDY DESIGN: In this prospective trial, 185 consecutive patients who underwent liver operations between 2014 and 2015 were studied. Volumetric and functional rates of remnant liver were measured using technetium 99m-galactosyl human serum albumin single-photon emission computed tomography/CT fusion imaging to evaluate post-hepatectomy remnant liver function. Remnant indocyanine green clearance rate using galactosyl (KGSA) (KGSA × functional rate) was used to predict future remnant liver function. Hepatectomy was considered safe for patients with remnant KGSA values ≥0.05, and the primary end point was to determine the accuracy and reliability of this criteria. The prediction of the 90-day major complication and mortality rates was assessed. RESULTS: Median hospital stay was 9 days and median ICU stay was 1 day, with only 1 in-hospital death (90-day mortality rate 0.5%). Overall morbidity rate evaluated according to the Clavien-Dindo classification was 9%. For post-hepatectomy liver failure definitions, the International Study Group of Liver Surgery definition was fulfilled in 14 patients (8%), with the majority being grade B (50%), compared with 2 patients (1%) fulfilling the "50-50" criteria, and 0 patients (0%) fulfilling the PeakBili >7 criteria. CONCLUSIONS: Results of this study showed that remnant KGSA provided information that allowed us to predict remnant liver function. This information will be important for surgeons when deciding on a treatment plan for patients with liver diseases. (ClinicalTrials.gov ID: NCT02013895).

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Okabayashi T, Shima Y, Morita S, et al. Liver Function Assessment Using Technetium 99m-Galactosyl Single-Photon Emission Computed Tomography/CT Fusion Imaging: A Prospective Trial. J Am Coll Surg. 2017. PMID: 28912030. doi:10.1016/j.jamcollsurg.2017.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。